There are four dengue virus (DENV) serotypes. Primary infection with one does not confer protective immunity against the others. We have reported previously that the marmoset (Callithrix jacchus) is a useful primary DENV infection model. It has been reported that secondary DENV infection with a heterotypic serotype induces viraemia kinetics and antibody responses that differ from those in primary infection. Thus, it is important to determine the utility of the marmoset as a model for secondary DENV infection. Marmosets were infected with heterologous DENV by secondary inoculation, and viraemia kinetics and antibody responses were analysed. The marmosets consistently developed high levels of viraemia after the secondary inoculation with heterologous DENV serotypes. IgM responses were lower compared with primary inoculation responses, whilst IgG responses were rapid and high. Neutralizing activities, which possessed serotype cross-reactive activities, were detected as early as 4 days after inoculation. In addition, infectious viraemia titres were higher when assayed with Fcc receptor-expressing baby hamster kidney (BHK) cells than when assayed with conventional BHK cells, suggesting the presence of infectious virus-antibody immune complexes. After secondary infection with heterotypic DENV, the marmosets demonstrated viraemia kinetics, IgM and IgG responses, and high levels of serotype cross-reactive neutralizing antibody responses, all of which were consistent with secondary DENV infection in humans. The results indicate the marmoset as a useful animal for studying secondary, as well as primary, DENV infection.
INTRODUCTION
The global burden of dengue is estimated to be over 300 million infections annually and has increased in recent decades (Bhatt et al., 2013) . The development of a safe and effective vaccine is key to reducing the disease burden and should be made a public health priority. There are currently no licensed vaccines or specific therapeutics for dengue. Considerations in DENV vaccine development include assessment of viraemia, immunogenicity, reactogenicity parameters, definition of correlates of protection and the potential roles of non-neutralizing antibodies in the antibodydependent enhancement of infection. A better understanding IP: 54.70.40.11
On: Sun, 30 Dec 2018 08:16:10 of the immune responses during protection and disease enhancement in secondary infection is critical for the development of vaccines and control strategies.
Animal models allow the evaluation of vaccine strategies by defining viraemia kinetics and antibody responses. Mice and non-human primates (NHPs) have been used previously as models for infection mechanism and vaccine development studies (Bente et al., 2005; Guriakhoo et al., 2002 Guriakhoo et al., , 2004 Guy et al., 2009; Halstead et al., 1973a, b; Koraka et al., 2007a) . Immunocompromised mice develop overt clinical signs upon dengue virus (DENV) infection, but further manipulation would be required in order to determine the susceptibility of the mouse model to clinical DENV serotypes and define its compatibility with human DENV infection (Shresta et al., 2006; Tan et al., 2010; Weiskopf et al., 2011) . With respect to predicting the accuracy of vaccine efficacy (reviewed by , the immunocompromised mouse model needs further manipulations for analysing cell-mediated immune responses, as the model lacks IFN-a/b/c. In contrast, the close genetic relationship that exists between NHPs and humans makes NHPs a suitable animal model for dengue vaccine and therapeutic studies. The NHP models have brought substantial advances in DENV vaccine development. Extensive studies using more than 20 NHP species including rhesus macaques, crab-eating macaques, owl monkeys and chimpanzees have shown that NHPs develop clinical signs including onset and duration of viraemia, and immune responses that reflect those of human DENV infection, but do not succumb to the disease (Bernardo et al., 2008; Clark et al., 2013; Halstead et al., 1973a; Ito et al., 2011; Lubiniecki & Tarr, 1977; Marchette et al., 1973; Omatsu et al., 2011; Onlamoon et al., 2010; Scherer et al., 1978; Schiavetta et al., 2003) . However, viraemia during secondary infection has been shown to be inconsistent in these models (Halstead et al., 1973a; Ito et al., 2011; Kochel et al., 2005; Koraka et al., 2007b; Whitehead et al., 1970) . Novel approaches using other NHPs that are consistent in their development of viraemia during secondary infection are needed to improve vaccine efficacy and disease mechanism studies (reviewed by Vaughn et al., 2008) .
Characterization of immunological responses after secondary infection is a key requirement for evaluating the protective efficacy of future candidate vaccines and vaccine delivery strategies. Macaques have been reported to show humoral and cellular immune responses after secondary challenge that are consistent with the responses observed in natural human infection (Halstead et al., 1973a; Scherer et al., 1972) . Vaccine efficacy studies using macaques have been implemented, resulting in an understanding of immune responses during secondary infection. We previously reported the marmoset (Callithrix jacchus) to be a useful animal for studies of DENV infection (Moi et al., 2013; Omatsu et al., 2011 Omatsu et al., , 2012 . Marmosets consistently develop high levels of viraemia upon primary DENV infection and have demonstrated protective immunity against homologous DENV challenge. In the present study, we evaluated the marmoset model in secondary heterotypic DENV infection. Marmosets that had been infected previously with one serotype of DENV were infected with heterologous DENV. Viraemia patterns and antibody responses in the secondary infection were analysed. The results indicated that the viraemia and antibody responses of marmosets after secondary DENV infection were consistent with those of humans and suggest the marmoset model as useful for studies of secondary, as well as primary, DENV infection.
RESULTS

Consistent development of viraemia in marmosets after secondary inoculation with heterotypic DENV
Levels of dengue viral RNA were assessed at days 0, 2, 3, 4, 7, 10 and 14 after inoculation with DENV (Table 1) . Eleven marmosets were inoculated with serotypes that differed from those used in primary inoculation. Three marmosets were inoculated with DENV-2 (experiment 1) and four marmosets were inoculated with DENV-1 (experiment 2) at 59 weeks after primary infection. Two marmosets were inoculated with DENV-1 (experiment 3) and two marmosets were inoculated with DENV-3 (experiment 4) at 83 weeks after primary DENV-2 infection ( Table 1) . All of the marmosets developed viraemia at days 2-14. The mean viraemia period was 7.5 days. Two marmosets were inoculated with DENV-1 in primary infection (experiment 5). Viraemia was detected from 2 to 10 days post-inoculation (p.i.), with peak levels comparable to those in the secondary inoculation. The results indicated that secondary infection with heterotypic DENV infection consistently resulted in viraemia in the marmoset model and suggested that primary infection in marmosets does not induce protective immunity against heterologous serotypes, results that are consistent with human DENV infection.
Detection of higher levels of viraemia using Fcc receptor (FccR)-expressing baby hamster kidney cells
Plasma samples from marmosets inoculated with DENV-1 in the secondary inoculation were analysed for viraemia levels using baby hamster kidney (BHK) and FccRexpressing BHK cells (Table 2) . Viraemia was detected in samples from marmosets D2D1-2, D2D1-3 and D2D1-4 when using FccR-expressing BHK cells but not when using BHK cells (Table 2, experiment 2). Viraemia levels were approximately 1 log higher in samples from marmosets D2D1-5 and D2D1-6 when using FccR-expressing BHK cells than when using BHK cells ( 
IgM and IgG antibody responses in marmosets after secondary DENV inoculation
Antibody responses after secondary DENV infection were analysed and compared with those after primary infection (Table 3) . IgM was first detected at day 4 after primary inoculation. As reported previously (Omatsu et al., 2011) , IgM levels increased rapidly from day 7 (Table 3 , experiment 5; Fig.  1 ). In the case of secondary infection, IgM was first detected at day 7 or 10 after secondary inoculation (Table 3 , experiments 1-4). The IgM levels increased but were lower than those in primary infection (Fig. 1b ). The mean positive : negative (P : N) ratio for IgM was higher for marmosets with primary infection (P : N529.6) at 14 days p.i. than for those with secondary infection (P : N510.4; Student's t-test, P,0.01).
IgG antibody responses were also analysed by ELISA (Table  4) . IgG was first detected at day 7 or 14 after primary inoculation. The levels increased gradually (experiment 5). All marmosets that were inoculated previously with DENV were positive for IgG prior to the secondary inoculation. The IgG antibody levels increased rapidly from day 7 after primary inoculation (experiment 2). The mean IgG antibody level in marmosets with secondary infection (P : N522.7) at 14 days p.i. was higher than that in marmosets with primary infection (P : N510.3; Student's t-test, P50.04). These results indicated that marmosets inoculated with heterotypic DENV exhibited secondary Secondary heterotypic inoculation (primary DENV-2, secondary DENV-1) IgM and IgG responses that were consistent with those found in human DENV infection ( Fig. 1 ).
Neutralizing antibody responses in marmosets after secondary DENV inoculation
Levels of neutralizing antibody to all four DENV serotypes were examined at days 0, 4, 7, 10 and 14 p.i. in primary (D1-1 and D1-2) and heterologous secondary (D2D1-1, D2D1-2, D2D1-3, D2D1-4, D2D1-5, D2D1-6, D2D3-1 and D2D3-2) infections using BHK cells and FccR-expressing BHK cells (Table 5) . Neutralizing antibody to DENV-2 was detected at day 0 in four of eight marmosets that received DENV-2 in the primary inoculation (experiments 2-4). Following secondary inoculation with DENV-1 or DENV-3, serotype cross-reactive antibodies were first detected as early as day 4. The levels increased rapidly in four marmosets (D2D1-5, D2D1-6, D2D3-1 and D2D3-2), which had undetectable levels of DENV neutralizing antibodies on the day of secondary inoculation (day 0). At day 14 after secondary inoculation, neutralizing antibody to four serotypes was detected in all marmosets with secondary infection by an assay using BHK and FccRexpressing BHK cells (Table 5 , experiments 2-4). After heterotypic secondary infection, however, neutralizing antibody titres were found to be higher when assayed using BHK cells than when using FccR-expressing BHK cells. Following primary inoculation with DENV-1, neutralizing antibody titre was first detected at day 7, and was highest to DENV-1 (experiment 5). The results suggested that neutralizing antibody responses of marmosets after both primary inoculation and secondary inoculation with heterologous serotypes were consistent with neutralizing antibody responses in humans. As seen in human DENV infection, serotype cross-reactive antibodies were detected during the early phase of secondary infection when using FccR-negative cells, but the titres were lower or undetectable when using FccR-expressing cells. The discrepancies between the two types of assay in neutralizing antibody titres were also consistent with the discrepancies of the same two assays when they are applied to humans. utility as a model for secondary DENV infection had not been confirmed. In the present study, viraemia and antibody responses in marmosets were analysed after secondary infection with heterotypic serotypes of DENV. The response exhibited in marmosets was similar to that in humans in that infection with one serotype did not confer protection to others. This was shown by the viraemia present in previously infected marmosets when they were infected with a different DENV serotype. High levels of viraemia were consistently detected in all of the marmosets after secondary DENV-1 and DENV-3 infection (Table 1) , and virus titres were as high as 7 log 10 genome copies ml 21 . The mean peak levels of viraemia, as detected by reverse transcription-PCR, did not differ significantly between primary and secondary DENV infection. In three marmosets, viraemia was detected for a longer duration (up to day 14 after secondary inoculation; Table 1 ). In an earlier study, which used 20 marmosets, none of the animals exhibited viraemia beyond day 10 after primary DENV inoculation (Omatsu et al., 2011) . Peak viraemia titres in macaques with secondary DENV-1 infection were reported to range from undetectable to 4 log p.f.u. in 0.5 ml (Halstead et al., 1973a) . Additionally, viraemia was also variable in white-handed gibbons with heterologous secondary DENV infection; viraemia was undetectable in some animals with heterologous secondary DENV infection (Whitehead et al., 1970) . In comparison, viraemia was detected in all marmosets (Table 1) , and peak viraemia titres in marmosets with secondary DENV-1 infection ranged from 2.4 to 4.4 log 10 p.f.u. ml 21 ( Table 2 ). The results demonstrated that marmosets consistently develop viraemia after secondary infection with heterologous DENV. The results also indicated that protective immunity to heterologous serotypes was absent. The results suggested that the peak viraemia titres in marmosets is not as high as those in human DENV infection , and further studies using a larger number of marmosets and manipulation of the marmoset model are needed to address the clinical and pathophysiological aspects of heterologous secondary infection in marmosets. Overall, the results suggest that marmosets could provide a reliable model for therapeutics and vaccine evaluation studies.
DISCUSSION
The antibody responses in DENV-infected humans have been well studied (Anantapreecha et al., 2005 (Anantapreecha et al., , 2007  reviewed by Rothman, 2010; WHO, 2009) . Antibody responses differ between primary and secondary infections (WHO, 2009) . In secondary infection, IgG and neutralizing antibody titres rise rapidly and are cross-reactive to all of the other DENV serotypes, whilst IgM levels are low or undetectable. In primary infection, IgM antibody is detected at the early phase (before IgG is detected), and the IgM levels are high. In the present study, IgG antibody was detected before secondary infection (day 0) in marmosets that had previously been infected with DENV. The IgG titres rose rapidly (as early as day 4 p.i.) to levels that were significantly higher than the titre levels in primary infection. These results, which suggest that IgG Table 5 .
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FccR-expressing BHK cells at indicated days p.i. Marmosets as a secondary DENV infection model antibodies and anamnestic memory persisted for more than a year (up to 83 weeks) after primary DENV inoculation, concur with the results of clinical studies in human dengue patients where DENV-specific IgG has been shown to remain detectable for up to a few years after primary infection (WHO, 2009) . In experimentally infected marmosets, IgM levels were also significantly lower during secondary infection than they were in primary infection. Thus, IgM and IgG antibody responses in marmosets after secondary infection mimic the antibody responses seen in human DENV infection.
It is known that neutralizing antibodies induced after secondary DENV infection are cross-reactive to the four DENV serotypes in human dengue infections (de Alwis et al., 2011; Xu et al., 2012; reviewed by Guzman et al., 2013; Zompi & Harris, 2013) . After secondary DENV infection, the marmosets of the present study exhibited high levels of neutralizing antibody titres to challenge infection not only from the serotypes with which they had previously been infected but also from serotypes to which they had not. Primary infection with one DENV serotype induced serotype-specific antibodies, and elicited life-long immunity, but only to that serotype. Immunity to other serotypes was short-lived. As in humans, marmosets that had low neutralizing titres before secondary infection (day 0) were susceptible to infection with heterologous serotypes. High titres of serotype cross-reactive neutralizing antibodies were induced in marmosets after secondary infection with heterotypic serotypes. The results indicate consistency between humans and marmosets in the neutralizing antibody patterns present after secondary DENV infection.
When FccR-expressing BHK cells were used, the viraemia titres that were detected in marmoset serum samples taken on days 2-7 after secondary infection were higher than those detected using BHK cells (Table 2 ). In samples from marmosets after primary DENV infection, the viraemia titres of assays using FccR-expressing BHK cells and BHK cells did not differ. The fact that the detected levels of viraemia in serum samples from secondary infection were 10 times higher in assays using FccR-expressing cells than they were in BHK cells suggests that infectious virusantibody immune complexes are formed during secondary infection. The presence of infectious immune complexes during secondary infection in marmosets is also consistent with secondary DENV infections in humans .
Animal challenge models afford methods to evaluate the efficacy of dengue vaccines and therapeutics. In the present study, the marmosets consistently developed viraemia and immune responses that mimicked those of secondary DENV infection in humans. Serotype cross-reactive antibody responses in marmosets during secondary DENV infection suggested the induction of strong T-and B-cell memories by primary DENV infection. Thus, our results suggest that marmosets are useful for vaccine efficacy studies, immune response studies and studies to better understand the immune mechanisms of protection and pathogenesis in secondary DENV infections.
METHODS
Ethics statement. All animal studies were conducted in accordance with the 'Guides for Animal Experiments Performed at National Institute of Infectious Diseases', approved by the Animal Welfare and Animal Care Committee of the National Institute of Infectious Diseases, Japan (approval nos 608011 and 609014), and the 'National Institute of Biomedical Innovation Rules and Guidelines for Experimental Animal Welfare', approved by the National Institute of Biomedical Innovation, Japan (approval nos 20-003 and 21-013). All animals were euthanized by cardiac exsanguination under pentobarbital-induced anaesthesia.
Animals. A total of 13 male marmosets were used. Marmosets were purchased from Clea Japan and caged singly at 27±2 uC in 50±10 % humidity with a 12 h light/dark cycle (lighting from 7 : 00 to 19 : 00) at the Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Tsukuba, Japan. Animals were fed twice a day with a standard marmoset diet (Clea New World Monkey Diet, CMS-1M; Clea Japan) supplemented with fruit, eggs and milk. Water was provided ad libitum. The animals were in a healthy condition and were confirmed to be negative for anti-DENV antibodies before inoculation with DENV.
DENV strains and propagation. DENV-1 02-17, DENV-1 01-44, DENV-2 DHF0663 (GenBank accession no. AB189122) and DENV-3 DSS1403 were the strains used for inoculation studies Omatsu et al., 2011) . All DENV strains were used within four passages on C6/36 cells. The culture supernatant from infected C6/36 cells was centrifuged at 800g for 5 min to remove cell debris and stored at 280 uC until use.
Infection of marmosets. In experiment 1, three marmosets (D3D2-1, D3D2-2 and D3D2-3) were inoculated subcutaneously with 6 log 10 p.f.u. DENV-3 DSS1403 for primary infection. Secondary inoculation with 7 log10 p.f.u. DENV-2 DHF0663 was administered 59 weeks (13 months) after the primary inoculation. In experiment 2, four marmosets were inoculated subcutaneously with 5 log 10 p.f.u. DENV-2 for primary infection. Secondary inoculation with 6 log 10 p.f.u. DENV-1 was administered 59 weeks (13 months) after the primary inoculation. Three of the four marmosets in experiment 2 (D2D1-1, D2D1-2 and D2D1-3) were inoculated with DENV-1 02-17, and one (D2D1-4) was inoculated with DENV-1 01-44. In experiment 3, two marmosets (D2D1-5 and D2D1-6) were inoculated subcutaneously with 4 log 10 p.f.u. DENV-2 for primary infection. Secondary inoculation with 6 log 10 p.f.u. DENV-1 was administered 83 weeks (19 months) after the first inoculation. In experiment 4, two marmosets (D2D3-1 and D2D3-2) were inoculated subcutaneously with 3 log 10 p.f.u. DENV-2 for primary infection. Secondary inoculation with 6 log 10 p.f.u. DENV-3 was administered 83 weeks (19 months) after the first inoculation. In experiment 5, which only examined primary infection, two marmosets (D1-1 and D1-2) were inoculated with DENV-1 (marmoset D1-1: DENV-1 02-17; marmoset D1-2: DENV-1 01-44). The amount of DENV transmitted by Aedes aegypti is reported to range from 3610 2 to 2610 5 50% mosquito infectious doses (Gubler & Rosen, 1976) . Recent studies showed that levels as high as .10 6 p.f.u. DENV can be transmitted by mosquitoes (Styer et al., 2007) . In the present study, marmosets were inoculated with 10 6 -10 7 p.f.u. DENV, which may be higher in comparison with levels transmitted by mosquitoes. All of the marmosets in the five experimental groups were observed for clinical signs at the time of blood collection. Blood samples were centrifuged at . Viral titres determined by RT-PCR were expressed as genome copies ml 21 . Thirteen marmosets in experiments 1-5 were quantified for viral RNA using RT-PCR (Table 1) . Of the 13 marmosets, plasma samples from seven marmosets were used for infectious virus quantification (experiments 2, 3 and 5) using BHK and FccR-expressing BHK cells (Table 2 ). Due to the lack of plasma samples from marmosets of experiments 1 and 4 for infectious virus titration, quantification for viraemia using a cell-based assay could not be carried out for these experiments. To determine viraemia levels in plasma samples, the samples were serially diluted 10-fold from 1 : 10 1 to 1 : 10 6 with Eagle's minimum essential medium (Sigma) supplemented with 10 % FBS. Fifty microlitres of diluted plasma samples were inoculated onto BHK and FccR-expressing BHK cell monolayers in 12-well plates. The plates were incubated for 1 h at 37 uC in 5 % CO 2 . After virus adsorption, the cells were overlaid with maintenance medium containing 1 % methylcellulose (Wako Pure Chemical Industries). The plates were incubated at 37 uC in 5 % CO 2 until visible plaques could be observed (5-7 days of incubation). The cells were fixed, stained with methylene blue and washed with water. Assays were conducted in duplicate. Viral titres were expressed as p.f.u. ml 21 using the following formula: (number of plaques per well6dilution)/inoculum volume.
Serological studies. DENV-specific IgM antibody was detected using a Dengue Fever IgM Capture ELISA (Focus), and DENV-specific IgG antibody was examined using a Dengue IgG Indirect ELISA (PanBio) in accordance with the manufacturers' instructions. The P : N ratio was calculated by the formula: absorbance of the test sample/ absorbance of a negative sample. Plasma samples collected from three DENV-naïve marmosets were used as the negative samples. P : N ratios of ,2 and ¢2 were considered to be negative and positive, respectively. All ELISAs were conducted in duplicate (Ito et al., 2011) .
Neutralizing antibody titres were determined by plaque reduction neutralization tests with four DENV strains (DENV-1 01-44, DENV-2 DHF0663, DENV-3 CH53489 and DENV-4 TVP360). Heat-inactivated plasma samples were serially diluted twofold from 1 : 10 to 1 : 640 with minimum essential medium (MEM) supplemented with 2 % FBS. Virus-antibody mixture was prepared by mixing 25 ml DENV at titres of 2000 p.f.u. ml 21 with 25 ml serially diluted serum samples to make up a final serum dilution of 1 : 20 to 1 : 1280. Control virus samples were prepared by mixing 25 ml DENV at titres of 2000 p.f.u. ml 21 with 25 ml MEM supplemented with 2 % FBS. Virusantibody mixture was incubated at 37 uC for 1 h. Fifty microlitres of virus-antibody mixture was inoculated onto BHK and FccRexpressing BHK cell monolayers in 12-well plates. After 5-7 days of inoculation the cells were fixed and stained, and the plaques were counted. A neutralizing assay was not carried out in some samples due to insufficient volume. Tests were conducted in duplicate. The neutralization titre was expressed as the maximum dilution of plasma sample that yielded a ¢50 % plaque reduction in the virus inoculum in comparison with a control virus sample.
Statistics. Results were expressed as the mean value of each group. Student's t-test was used to compare the mean titres and determine statistical significance. The statistical package in Microsoft Excel was used for statistical calculations. A P value of ,0.05 was considered to be statistically significant.
